Palvella Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Palvella Therapeutics, Inc. (PVLA) had Available-for-sale Securities, Amortized Cost Basis of $53.38 million as of 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-03-18
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $53.38M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $45.49M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-12-31 | $53.38M 10-K · filed 2019-03-18 |
| 2017-12-31 | $45.49M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |